September 14, 2018
Akorn Inc. is recalling more than 23,000 bottles of ethosuximide capsules, USP, 250 mg, according to the September 12, 2018, US Food and Drug Administration (FDA) Enforcement Report. Affected capsules tested out-of-specification for an impurity.
The recall is for 100-count bottles of ethosuximide from lots 1165280100 and 1165280101 (Exp. 3/19). The bottles, which were manufactured for VersaPharm Incorporated by Swiss Caps AG, were distributed throughout the United States.
Akorn voluntarily initiated the recall August 24, 2018. The FDA designated it Class II September 7, 2018, signaling use of the drug carries with it the possibility of temporary or medically reversible adverse health consequences. A chance of serious harm also exists, although the likelihood is remote.
Ethosuximide is a prescription anticonvulsant medication used to control seizures in patients with epilepsy.
For more Pharmacy Learning Network articles, visit the homepage
To learn about Pharmacy Learning Network Live meetings, click here